Mental health app Lissun invests $3 million in AI integration
Indian mental health platform Lissun has secured $2.5 million in a pre-Series A funding round led by RPSG Capital Ventures.
With the new funding, the startup plans to integrate AI into its suite of digital mental health solutions targeting businesses, schools, and families of children with neurodevelopmental disabilities. The new funding will also be used to expand services and grow the team.
The proceeds from this new investment round bring the total investment amount to $5 million. Lissun last raised more than $1 million in seed funding in September of the previous year.
Seoul Asan Medical Center, the first in Korea to prescribe DTx for vision loss
Asan Medical Center (AMC) in Seoul has begun prescribing domestically produced digital treatments for visual impairment caused by stroke.
The mobile-based application Vivid Brain provides training through virtual reality to improve users’ responses to visual stimuli.
AMC officially prescribed the solution in September, five months after receiving approval from the Korean government. Third for local DTx.
AMC Professor Dong-Hwa Kang, who developed Vivid Brain with local company Nunaps, now plans to expand DTx to hospitals at home and abroad.
Neurophet’s Latest Collaboration to Predict Alzheimer’s Disease Risk
Neurophet, a domestic medical imaging AI company, announced a new partnership to develop a new Alzheimer’s disease diagnostic platform.
The company said in a statement that it would collaborate with Aribio, a domestic biotechnology company developing treatments for neurodegenerative diseases.
They plan to integrate Neurophet’s MRI-based image analysis software with Aribio’s blood-based Alzheimer’s diagnostic test to detect early-stage patients with Alzheimer’s-positive amyloid beta protein deposits in their brains.
According to a press release, their solution is to increase access to Alzheimer’s testing and reduce costly repeat testing with amyloid-PET imaging.
Neurophet’s collaboration with Aribio builds on existing research from a global clinical trial of Aribio’s phase 3 oral Alzheimer’s drug, AR1001.
Last July, Neurophet unveiled Neurophet AQUA AD, its latest Alzheimer’s treatment prescription and monitoring software.
